Recombinant Human ALK-7 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human ALK-7 Fc Chimera Protein, CF Summary

• Details of Functionality: Bioassay data are not available.
• Source: Chinese Hamster Ovary cell line, CHO-derived human ALK-7 protein
  

  Human ACVR1C (Leu26-Glu113) Accession # P24394.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• N-terminal Sequence: Leu26
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 36 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 51-62 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 250 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ALK-7 Fc Chimera Protein, CF

• activin A receptor, type IC
• Activin receptor type IC
• activin receptor type-1C
• Activin receptor-like kinase 7
• Activin RIC
• ACTR-IC
• ACVR1C
• ACVRLK7
• ALK7
• ALK-7
• ALK7ALK-7
• EC 2.7.11
• EC 2.7.11.30

Background

Transforming growth Factor beta (TGF-beta ) superfamily ligands exert their biological activities via binding to heteromeric receptor complexes of two types (I and II) of serine/threonine kinases. Type II receptors are constitutively active kinases that phosphorylate type I receptors upon ligand binding. In turn, activated type I kinases phosphorylate downstream signaling molecules including the various smads. Transmembrane proteoglycans, including the type III receptor (betaglycan) and endoglin, can bind and present some of the TGF-beta superfamily ligands to type I and II receptor complexes and enhance their cellular responses. Seven type I receptors (also termed activin receptor like kinase (ALK)) and five type II receptors have been isolated from mammals. ALK -2, -3, -4, -5, and -6 are also known as Activin R1A, BMPR-1A, Activin R1B, TGF-beta R1, and BMPR-1B, respectively, reflecting their ligand preferences. ALK-7 is also known as Activin receptor type-1C, ACTR-1C, and ACVR1C. It shares with other type I receptors a cysteine-rich domain with conserved cysteine spacing in the extracellular region, and a glycine and serine rich domain (the GS domain) preceding the kinase domain. It is primarily expressed in the central nervous system, pancreatic islets, and adipose tissue. ALK-7 known ligands, such as Nodal, Activin B, and growth differentiation factor (GDF), can activate Smads and other signaling pathways which regulate cell proliferation, differentiation, and apoptosis in various cells. It has also been shown that orphan ligand, Activin C, signals through activin receptor-like kinase 7. Meanwhile, in mature murine adipocytes, Activin E invoked a SMAD2/3 response via ALK7, like Activin C.

1. ten Dijke, P. et al. (1993) Oncogene 8:2879.
2. ten Dijke, P. et al. (1994) Science 264:101.
3. Ryden, M. et al. (1996) J. Biol. Chem. 271:30603.
4. Roberts, H.J. et al. (2003) Biol Reprod 68:1719-1726.
5. Goebel, E. et al. (2022) eLife 11:e78197.
6. Vestal, K.A. et al. (2024) Biochem. J. 481:547-564.